9,468 Shares in BioNTech SE (NASDAQ:BNTX) Acquired by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of BioNTech SE (NASDAQ:BNTX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 9,468 shares of the company’s stock, valued at approximately $1,125,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Covestor Ltd grew its stake in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after buying an additional 133 shares in the last quarter. Planning Capital Management Corp grew its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. grew its stake in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after buying an additional 238 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Up 4.5 %

NASDAQ:BNTX opened at $113.13 on Friday. The company has a fifty day moving average of $113.60 and a 200 day moving average of $97.75. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $27.12 billion, a P/E ratio of -53.87 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same period in the prior year, the business earned $0.73 EPS. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, research analysts predict that BioNTech SE will post -3.68 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. TD Cowen cut their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $138.79.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.